1513 related articles for article (PubMed ID: 15199112)
1. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
[TBL] [Abstract][Full Text] [Related]
3. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
5. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
6. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
7. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
8. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
[TBL] [Abstract][Full Text] [Related]
9. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
10. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
Kurokawa H; Lenferink AE; Simpson JF; Pisacane PI; Sliwkowski MX; Forbes JT; Arteaga CL
Cancer Res; 2000 Oct; 60(20):5887-94. PubMed ID: 11059787
[TBL] [Abstract][Full Text] [Related]
12. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
Zhao W; Zhang Q; Kang X; Jin S; Lou C
Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
[TBL] [Abstract][Full Text] [Related]
13. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
14. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
[TBL] [Abstract][Full Text] [Related]
16. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
17. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
19. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
Sengupta S; Schiff R; Katzenellenbogen BS
Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]